1.82  0.14 (8.33%)		12-06 16:00
Open: 1.68 High: 1.9299 Volume: 665,308		Pre. Close: 1.68 Low: 1.615 Market Cap: 122(M)

Short term
Mid term
Targets	6-month :	2.52	1-year :	2.95
Resists	First :	2.16	Second :	2.52
Pivot price	1.65
Supports	First :	1.51	Second :	1.12
MAs	MA(5) :	1.67	MA(20) :	1.64
	MA(100) :	5.95	MA(250) :	8.63
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	52.9	D(3) :	50
RSI	RSI(14): 47
52-week	High :	14.18	Low :	1.12

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PROK ] has closed below upper band by 30.4%. Bollinger Bands are 69.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.93 - 1.94	1.94 - 1.95
Low:	1.6 - 1.61	1.61 - 1.61
Close:	1.81 - 1.82	1.82 - 1.83

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Fri, 01 Dec 2023
ProKidney: Getting Easier To Comprehend Now (NASDAQ:PROK) - Seeking Alpha

Thu, 30 Nov 2023
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer - ProKidney (NASDAQ:PROK) - Benzinga

Fri, 17 Nov 2023
Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation - Simply Wall St

Fri, 17 Nov 2023
ProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 16 Nov 2023
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK) - Yahoo Finance

Tue, 14 Nov 2023
ProKidney Reports Third Quarter Financial Results - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	67 (M)
Shares Float	49 (M)
Held by Insiders	22.3 (%)
Held by Institutions	65.3 (%)
Shares Short	10,500 (K)
Shares Short P.Month	8,770 (K)

EPS	-0.58
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-17.74
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-20.1 %
Return on Equity (ttm)	-29.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.3
Qtrly Earnings Growth	0 %
Operating Cash Flow	-80 (M)
Levered Free Cash Flow	-68 (M)

PE Ratio	-3.14
PEG Ratio	0
Price to Book value	-0.11
Price to Sales	0
Price to Cash Flow	-1.52

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.